NCT00487136 - Interaction Between ABT-335, Rosuvastatin and Warfarin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Healthy

Interventions

DRUG

Warfarin

Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.

DRUG

warfarin plus ABT-335 plus rosuvastatin 5 mg

Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.

DRUG

warfarin plus ABT-335 plus rosuvastatin 20 mg

Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.

Trial Locations (1)

72205

Site Ref # / Investigator 5290, Little Rock